Trastuzumab (Herceptin), a monoclonal antibody against subdomain IV of the HER2extracellular domain (ECD), combined with chemotherapy can significantly improve the prognosis of HER2-positive BC patients compared with chemotherapy alone, which has been demonstrated in the Cochrane meta-analyses [7, 8]. Here, ERBB2 is linked to breast cancer.